LEO-27847
- Generic Name
- LEO-27847
LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 72
- Registration Number
- NCT01167309
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇵🇱Centralny Szpital Kliniczny MON, Warszawa, Poland
The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01141179
- Locations
- 🇨🇦
Anapharm, Toronto, Ontario, Canada
LEO 27847 - A Study in Healthy Male Subjects
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 48
- Registration Number
- NCT01007383
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath